Boston Scientific BSX, a prominent global player in cardiovascular technology, is well positioned to capitalize on the robust ...
Pulmonary hypertension (PH) is classified as precapillary, isolated postcapillary pulmonary hypertension (IpcPH), combined postcapillary and precapillary (CpcPH), or exercise PH. IpcPH associated with ...
Boston Scientific’s CHAMPION-AF trial found the Watchman FLX left atrial appendage closure device to be statistically superior to leading blood thinners in reducing major bleeding, while matching them ...
This month’s list features a tribute to Eugene Braunwald, dyslipidemia guidelines, abundant news from ACC, and more.
Boston Scientific (NYSE:BSX) released new clinical trial results for its FARAPULSE PFA Platform and WATCHMAN LAAC at Heart Rhythm 2026. The AVANT GUARD trial reported superiority of FARAPULSE PFA over ...
Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's FARAPULSE™ Pulsed Field Ablation (PFA) Platform and WATCHMAN™ Left Atrial Appendage Closure (LAAC) ...
We used data from a prospective cohort of patients with acute ischemic stroke undergoing cardiac computed tomography during the acute stroke imaging protocol. We compared characteristics, functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results